Author

Michelle Trapp

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

OpenAlex ID: A5017847251

Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).

2017 · Yago Nieto, Shi-Ming Tu, et al. · Journal of Clinical Oncology · 5

Prospective Collection of Patient Ancestry Information As Standard-of-Care

2025 · Jessica Pena, Kelly Acosta, et al. · Transplantation and Cellular Therapy

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

2017 · Yago Nieto, Peter F. Thall, et al. · Blood

Works count: 3

Citation count: 5

H-index: 1

I10-index: